FDA NSAID Panel Nixes Naproxen Heart Safety Claim

(MedPage Today) -- In 16-9 vote, the FDA advisory committee assessing NSAID safety said the warning label on naproxen should not be changed to suggest it has a better cardiovascular risk profile than other drugs in this class.

http://www.medpagetoday.com/PainManagement/PainManagement/44253

Source: MedPage Today Psychiatry - February 12, 2014 Category: Psychiatry Source Type: news